Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
about
New drugs in prostate cancerTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerPersistent androgen receptor addiction in castration-resistant prostate cancerODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentTargeting the adaptive molecular landscape of castration-resistant prostate cancerNovel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate CancerMolecular pathways and targets in prostate cancerDiscovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapiesDarolutamide (ODM-201) for the treatment of prostate cancerCurrent advances in intratumoral androgen metabolism in castration-resistant prostate cancer.Translational and clinical implications of the genetic landscape of prostate cancer.Non-Genomic Actions of the Androgen Receptor in Prostate CancerEnzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancerSynergistic action of image-guided radiotherapy and androgen deprivation therapy.Novel agents for castration-resistant prostate cancer: Early experience and beyond.Emerging agents for the therapy of advanced prostate cancer.Cellular determinants and microenvironmental regulation of prostate cancer metastasis.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.Multifaceted and personalized therapy of advanced prostate cancer.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Prostate cancer: Developing novel approaches to castration-sensitive disease.Progress in the mechanism and drug development of castration-resistant prostate cancer.Drug discovery in advanced prostate cancer: translating biology into therapy.Androgen receptor variation affects prostate cancer progression and drug resistance.Clinical relevance of androgen receptor alterations in prostate cancer.Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.A mini-review of quality of life as an outcome in prostate cancer trials: patient-centered approaches are needed to propose appropriate treatments on behalf of patients.Recent discoveries and developments of androgen receptor based therapy for prostate cancerEnzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
P2860
Q26745948-600FE1A8-4BE2-4ED3-B67B-3970FEC977E2Q26750620-14EDFD8F-F7C8-4D60-ABD7-81314C7FB5AAQ26766638-CFA3E774-4C46-4FEB-A909-2EEEACFACBDCQ26777163-22D4CFEB-8368-4477-BAA4-EC36E8580838Q26796568-3E980266-DCE9-4C0D-8095-4A37CF121CEDQ27009424-EA46B8ED-321A-4A1D-8ADC-C0D4A0084889Q27022821-E52FD67A-E53B-487A-AC7E-168A61FE7E78Q28067556-DBD1B4B7-67F0-4CF9-ADED-DBBC8D9F40CFQ34365632-08E1B16B-560B-4E1E-ACF6-3665DBA31EBAQ34483362-696A4F94-4098-43CF-8385-BD7F97248996Q34556466-2C44C01D-656B-4F58-90D6-9E70A5638774Q36970812-749CACEA-3DD1-4FAD-9442-9472B59B9581Q37270512-AF07DA5F-9EDC-4E55-8203-B92287EEDD8DQ37588620-3A99096E-3E56-4B39-BA4C-EB93DF54CDA2Q38276818-8CBE276B-A862-4A08-A7AD-7FB4036D3B05Q38387844-689E6156-5AC5-45C2-B505-BE13104A74DBQ38574684-B5FFACED-3390-4081-B3C5-A9643ABAB5DFQ38586459-D9CD4542-A552-4151-A169-444BA8061687Q38730590-AC98E0EE-8E5E-46CD-A26C-42A4F683594BQ38765489-8E4BAD1C-475B-4478-A3CD-C15CB464280EQ38775459-CC7DC906-8BC5-4F77-82D4-07939E3CD2EFQ38780436-C3CFC1F5-5BC5-4787-B69F-5039FD409695Q38797560-003B56C4-2A0E-4EAC-924E-5D05C96990C8Q38801270-BBFC594D-EA35-451B-AB13-B82DF5C3D9E4Q38826609-392E5A84-B639-483E-A7A5-DD94D320F64FQ38839110-895F442E-7D60-484F-895D-2AAAC6C801BEQ38977288-F9020E52-9DED-41AA-A4CC-D49FBED35360Q42377108-C842E4ED-39D5-4584-9472-6A223CF081ABQ44964713-CFEC0677-873E-413C-B647-FAAA3E0097E9Q50074169-F0B33D53-894B-4530-99AF-F458A9520486Q52677958-E5D03026-6075-4DC1-9F4D-456CEFB8817FQ55252859-10F8454B-A36C-46FF-91BC-6EE24F547842Q56621622-D2188AF7-4A2D-4469-A231-ED59980A7E35Q58698705-B4F436DE-BDBB-4615-A521-5BB5251546B0
P2860
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Activity and safety of ODM-201 ...... phase 2 dose expansion trial.
@ast
Activity and safety of ODM-201 ...... phase 2 dose expansion trial.
@en
Activity and safety of ODM-201 ...... tion-resistant prostate cancer
@nl
type
label
Activity and safety of ODM-201 ...... phase 2 dose expansion trial.
@ast
Activity and safety of ODM-201 ...... phase 2 dose expansion trial.
@en
Activity and safety of ODM-201 ...... tion-resistant prostate cancer
@nl
prefLabel
Activity and safety of ODM-201 ...... phase 2 dose expansion trial.
@ast
Activity and safety of ODM-201 ...... phase 2 dose expansion trial.
@en
Activity and safety of ODM-201 ...... tion-resistant prostate cancer
@nl
P2093
P50
P1433
P1476
Activity and safety of ODM-201 ...... phase 2 dose expansion trial.
@en
P2093
ARADES study group
Andrew Protheroe
Annamari Vuorela
Christophe Massard
John Aspegren
Jorge A Garcia
Leena Mattila
Mika Mustonen
Nicholas James
Peter Langmuir
P304
P356
10.1016/S1470-2045(14)70240-2
P577
2014-06-25T00:00:00Z